A team led by Mass General Brigham researchers demonstrated that inebilizumab reduced the risk of symptoms by 87% in patients with the rare affliction known as immunoglobulin G4–related disease (IgG4- ...

As people, especially women, pass the age of 50, they become more at risk for Sjögren's syndrome. We asked a doctor about the ...